Her case illustrates the need for still more options to prevent or treat migraine attacks, even as the CGRP success story showed there’s hope for new medicines. “CGRP has really paved the way ...

Associate Health Minister with responsibility for Pharmac David Seymour is pleased to see Pharmac continue to increase ...

Multiple Sclerosis NZ is calling for Pharmac to adopt a a cost benefit model when it comes to funding new drugs.

“The results of this systematic review and network meta-analysis offer the best available evidence to guide the choice of acute oral drug interventions for migraine episodes,” the authors write.

Another study ... exercise and medication can help. Di Vincenzo A, Beghetto M, Vettor R, et al. Effects of surgical and non-surgical weight loss on migraine headache: a systematic review and ...

Emgality (galcanezumab-gnlm) is prescribed for migraine prevention and to treat ... Your doctor will recommend another drug to manage your condition. Keeping track of side effects During your ...

New hope could be on the horizon for ALS patients in the form of a "breakthrough" drug, researchers say. Neuvivo, a California biopharmaceutical company that develops therapies for ...

This page gives information on Cobenfy, a ground-breaking new drug to treat schizophrenia. It has been licensed for use in the United States, but not yet in England. This information is for people who ...

A new study says the medicinal cannabis scheme in New Zealand has greatly enhanced access and reduced prices for legal ...

ShiraTronics, a clinical-stage medical device company developing neurostimulation therapies for chronic migraine patients, ...

The report explains that Pharmac’s current funding model is a cost utility analysis (CUA), which is a subset of cost effectiveness analysis. In this, Pharmac weighs up the direct healthcare costs and ...

A new study has revealed the order of Covid-19 XEC symptoms that could help differentiate the new variant from other ...